Table 2.
Multivariable Cox regression analyses of BCFI and OS in (A) all patients and stratified by (B) nodal status, (C) ER status, and (D) AI treatment in patients with ER+ tumors.
| A | |||||
| Recurrence-risk HR (95% CI) | Death due to any cause HR (95% CI) | ||||
| Ever MHT, yes | 1.21 (0.83–1.77) | 0.81 (0.55–1.19) | |||
| Age, years | 1.00 (0.98–1.03) | 1.06 (1.03–1.08) | |||
| BMI, ≥25 kg/m2 | 1.54 (1.06–2.25) | 2.00 (1.32–3.04) | |||
| Invasive tumor size > 20 mm or muscular or skin involvement, yes | 1.75 (1.18–2.59) | 1.60 (1.07–2.40) | |||
| Axillary lymph node positive, yes | 1.33 (0.91–1.94) | 1.54 (1.04–2.29) | |||
| Histological grade III, yes | 1.06 (0.65–1.72) | 1.11 (0.68–1.82) | |||
| ER+, yes | 0.52 (0.30–0.92) | 0.45 (0.26–0.76) | |||
| B | |||||
| Axillary lymph node status | Node positive HR (95% CI) | Node negative HR (95% CI) | Node positive HR (95% CI) | Node negative HR (95% CI) | |
| Ever MHT, yes | 0.72 (0.41–1.27) | 1.88 (1.11–3.17) | 0.48 (0.27–0.86) | 1.27 (0.74–2.17) | |
| Age, years | 1.02 (0.99–1.06) | 0.99 (0.95–1.02) | 1.05 (1.02–1.08) | 1.07 (1.03–1.11) | |
| BMI, ≥ 25 kg/m2 | 1.84 (1.01–3.34) | 1.36 (0.82–2.24) | 1.81 (0.97–3.41) | 2.14 (1.22–3.73) | |
| Invasive tumor size > 20 mm or muscular or skin involvement, yes | 1.71 (0.99–2.95) | 1.99 (1.11–3.56) | 1.57 (0.89–2.76) | 1.69 (0.94–3.03) | |
| Histological grade III, yes | 1.22 (0.64–2.35) | 0.82 (0.39–1.71) | 0.93 (0.45–1.90) | 1.29 (0.65–2.54) | |
| ER+, yes | 0.72 (0.32–1.66) | 0.38 (0.18–0.83) | 0.56 (0.25–1.28) | 0.36 (0.18–0.74) | |
| C | |||||
| ER status | ER positive HR (95% CI) | ER negative HR (95% CI) | ER positive HR (95% CI) | ER negative HR (95% CI) | |
| Ever MHT, yes | 0.95 (0.63–1.42) | 3.99 (1.40–11.33) | 0.72 (0.47–1.12) | 1.18 (0.50–2.79) | |
| Age, years | 1.01 (0.98–1.03) | 0.98 (0.90–1.05) | 1.05 (1.03–1.08) | 1.06 (1.00–1.13) | |
| BMI, ≥ 25 kg/m2 | 1.58 (1.05–2.39) | 1.68 (0.63–4.51) | 1.99 (1.25–3.17) | 2.07 (0.78–5.47) | |
| Invasive tumor size > 20 mm or muscular or skin involvement, yes | 1.53 (0.99–2.37) | 3.27 (1.23–8.70) | 1.42 (0.89–2.26) | 2.24 (0.92–5.46) | |
| Axillary lymph node positive, yes | 1.44 (0.95–2.19) | 1.38 (0.55–3.49) | 1.76 (1.12–2.76) | 1.13 (0.48–2.63) | |
| Histological grade III, yes | 1.25 (0.73–2.12) | 0.82 (0.31–2.18) | 1.13 (0.62–2.03) | 1.30 (0.51–3.32) | |
| D | |||||
| AI treatment, ER+ only HR (95% CI) | AI-treated HR (95% CI) | Non-AI-treated HR (95% CI) | AI-treated HR (95% CI) | Non-AI-treated HR (95% CI) | |
| Ever MHT, yes | 0.46 (0.25–0.84) | 1.81 (1.01–3.24) | 0.41 (0.22–0.77) | 1.23 (0.65–2.30) | |
| Age, years | 1.03 (0.99–1.07) | 0.99 (0.95–1.03) | 1.06 (1.02–1.10) | 1.05 (1.01–1.09) | |
| BMI, ≥25 kg/m2 | 1.66 (0.88–3.13) | 1.72 (0.98–3.02) | 2.16 (1.07–4.37) | 2.00 (1.05–3.80) | |
| Invasive tumor size > 20 mm or muscular or skin involvement, yes | 1.78 (0.98–3.22) | 1.56 (0.78–3.11) | 1.65 (0.89–3.07) | 1.30 (0.61–2.77) | |
| Axillary lymph node positive, yes | 2.07 (0.98–4.39) | 2.23 (1.02–4.86) | 1.38 (0.64–2.80) | 3.51 (1.63–7.54) | |
| Histological grade III, yes | 1.65 (0.85–3.21) | 0.84 (0.29–2.44) | 1.48 (0.73–3.01) | 0.62 (0.18–2.18) | |